Home LiteratureArticle Details
PMID: 16413663 Published · ppublish English Journal Article

The predictive value of p53, p27(kip1), and alpha-catenin for progression in superficial bladder carcinoma.

European urology ·Vol. 50 ·No. 1 ·2006-07-00 ·Pages 76-82

Schrier BP, Vriesema JL, Witjes JA, Kiemeney LA, Schalken JA

Abstract

The aim of the study was to confirm the predictive value of cell cycle regulatory proteins, p53 and p27(kip1), and the cell adhesion complex protein alpha-catenin, for progression in patients with superficial bladder carcinoma. Forty-one patients with progression after primary superficial bladder carcinoma were individually matched to patients with nonprogressive superficial bladder carcinoma. Matching was done for sex, age, tumor stage and grade, concomitant carcinoma in situ (CIS), and duration of follow-up. Immunohistochemical analysis of p53, p27(kip1), and alpha-catenin was performed on each primary bladder tumor. Analysis for the p53 mutation was done on 41 bladder tumor samples. Conditional logistic regression analysis was used to establish the prognostic value of immunohistochemical p53, p27(kip1), and alpha-catenin status. The independent odds ratios for progression were 0.3 (95% confidence interval [CI], 0.1-1.2) for high-risk p27(kip1), 3.4 (95%CI, 0.8-15.2) for high-risk p53, and 2.5 (95%CI, 0.6-10.3) for high-risk alpha-catenin. Combinations of different markers had no synergistic effects. Two p53 mutations were found in 21 DNA samples analyzed from nonprogressive tumors (9.5%); 8 of 20 samples (40%) from progressive tumors showed a p53 mutation. The probability of high-risk p53 immunostaining was 5-fold increased in case of mutations in p53. The estimated positive predictive value of high-risk p53 or high-risk alpha-catenin was about 23%. We confirm that high-risk p53, p53 mutation, and alpha-catenin immunohistochemistry do have an additional prognostic value in primary bladder carcinoma. However, the clinical value of the investigated parameters remains limited.

MeSH Terms
Cyclin-Dependent Kinase Inhibitor p27/metabolism Disease Progression Humans Immunohistochemistry Mutation Neoplasm Invasiveness Tumor Suppressor Protein p53/genetics,metabolism Urinary Bladder Neoplasms/metabolism,pathology alpha Catenin/metabolism
Chemicals
Tumor Suppressor Protein p53 alpha Catenin Cyclin-Dependent Kinase Inhibitor p27
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Schrier Barthold Ph
Department of Urology, Radboud University Nijmegen, Medical Centre, Geert Grooteplein 10, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. b.schrier@jbz.nl
Vriesema Jessica L J
Witjes J Alfred
Kiemeney Lambertus A L M
Schalken Jack A
Article Info
Journal
European urology
Abbr.
Eur Urol
ISSN
0302-2838
Published
2006-07-00
Epub
2006-00-06
Pages
76-82
Language
English
Region
Switzerland
NLM ID
7512719
Subset
IM
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com